Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
recombinant-FSH + human menopausal gonadotropin
- Development stage
- Unknown
- Lead developer
- Damascus University
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Subcutaneous
01
Overview
A combination therapy consisting of recombinant follicle-stimulating hormone (rFSH) and human menopausal gonadotropin (hMG), also known as menotropin, used for controlled ovarian stimulation (COS) in assisted reproductive technology (ART) procedures such as IVF and ICSI. rFSH is a recombinant protein that selectively binds to and activates the follicle-stimulating hormone receptor (FSHR), promoting the recruitment and growth of multiple ovarian follicles. hMG is a purified extract derived from the urine of postmenopausal women that contains both FSH and luteinizing hormone (LH) activity. The addition of hMG to rFSH protocols is intended to provide supplemental LH activity, which is essential for ovarian steroidogenesis and may improve oocyte quality and maturation in specific patient populations, including those with polycystic ovary syndrome (PCOS). This specific combination was evaluated by Damascus University in a Phase 4 clinical trial comparing the effects of GnRH agonist and antagonist protocols on oocyte morphology.
- Other names
- rFSH + hMGrecombinant follicle stimulating hormone + menotropinrecombinant-FSH + human Menopausal Gonadotropin
02
Targets
FSHR (Follicle-stimulating hormone receptor)LHCGR (Luteinizing hormone/choriogonadotropin receptor)
Beyond the preview
Go deeper on recombinant-FSH + human menopausal gonadotropin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on recombinant-FSH + human menopausal gonadotropin.